LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 316

Search options

  1. Book: Pediatric malignancies

    Parham, David M. / Khoury, Joseph D. / McCarville, M. Beth

    pathology and imaging

    2015  

    Author's details David M. Parham ; Joseph D. Khoury ; M. Beth McCarville ed
    Language English
    Size X, 429 S. : zahlr. Ill.
    Publisher Springer
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT018532014
    ISBN 978-1-4939-1728-0 ; 1-4939-1728-5 ; 9781493917297 ; 1493917293
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: WHO or International Consensus Classification: Is the Difference Worth It?

    Cree, Ian A / Khoury, Joseph D

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 31, Page(s) 4937–4938

    MeSH term(s) Humans ; Consensus ; Societies, Medical ; World Health Organization
    Language English
    Publishing date 2023-07-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.01172
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Myelodysplastic neoplasms evolving from inherited bone marrow failure syndromes / germline predisposition syndromes: Back under the microscope.

    Elghetany, M Tarek / Patnaik, Mrinal M / Khoury, Joseph D

    Leukemia research

    2024  Volume 137, Page(s) 107441

    Abstract: Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia ( ...

    Abstract Inherited bone marrow failure syndromes and germline predisposition syndromes (IBMFS/GPS) are associated with increased risk for hematologic malignancies, particularly myeloid neoplasms, such as myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML). The diagnosis of MDS in these syndromes poses difficulty due to frequent bone marrow hypocellularity and the presence of some degree of dysplastic features related to the underlying germline defect causing abnormal maturation of one or more cell lines. Yet, the diagnosis of MDS is usually associated with a worse outcome in several IBMFS/GPS. Criteria for the diagnosis of MDS in IBMFS/GPS have not been standardized with some authors suggesting a mixture of morphologic, cytogenetic, and genetic criteria. This review highlights these challenges and suggests a more standardized approach to nomenclature and diagnostic criteria.
    MeSH term(s) Humans ; Bone Marrow Diseases/genetics ; Bone Marrow Diseases/complications ; Bone Marrow Diseases/pathology ; Congenital Bone Marrow Failure Syndromes/complications ; Myelodysplastic Syndromes/diagnosis ; Myelodysplastic Syndromes/genetics ; Myelodysplastic Syndromes/pathology ; Leukemia, Myeloid, Acute/genetics ; Genetic Predisposition to Disease ; Germ Cells/pathology
    Language English
    Publishing date 2024-01-23
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2024.107441
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Colonic myeloid sarcoma with mutated

    Tashakori, Mehrnoosh / Khoury, Joseph D

    EJHaem

    2022  Volume 3, Issue 2, Page(s) 555–556

    Language English
    Publishing date 2022-02-08
    Publishing country United States
    Document type Journal Article
    ISSN 2688-6146
    ISSN (online) 2688-6146
    DOI 10.1002/jha2.377
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Where diagnosis for myelodysplastic neoplasms (MDS) stands today and where it will go: The role of flow cytometry in evaluation of MDS.

    Wang, Wei / Khoury, Joseph D

    Cytometry. Part B, Clinical cytometry

    2022  Volume 104, Issue 1, Page(s) 12–14

    MeSH term(s) Humans ; Flow Cytometry ; Neoplasms ; Myelodysplastic Syndromes/diagnosis ; Immunophenotyping
    Language English
    Publishing date 2022-12-27
    Publishing country United States
    Document type Editorial
    ZDB-ID 2099657-3
    ISSN 1552-4957 ; 1552-4949 ; 0196-4763
    ISSN (online) 1552-4957
    ISSN 1552-4949 ; 0196-4763
    DOI 10.1002/cyto.b.22110
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Book: Atlas of lymph node pathology

    Miranda, Roberto N. / Khoury, Joseph D. / Medeiros, L. Jeffrey

    (Atlas of anatomic pathology)

    2013  

    Author's details Roberto N. Miranda ; Joseph D. Khoury ; L. Jeffrey Medeiros
    Series title Atlas of anatomic pathology
    Keywords Medicine ; Oncology ; Pathology ; Medicine & Public Health
    Language English
    Size XIX, 530 S. : zahlr. Ill.
    Publisher Springer
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT018097226
    ISBN 978-1-4614-7958-1 ; 9781461479598 ; 1-4614-7958-4 ; 1461479592
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  7. Article ; Online: Blastic Plasmacytoid Dendritic Cell Neoplasm.

    Khoury, Joseph D

    Current hematologic malignancy reports

    2018  Volume 13, Issue 6, Page(s) 477–483

    Abstract: Purpose of review: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood.: Recent findings: TCF4 ... ...

    Abstract Purpose of review: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare malignancy derived from plasmacyoid dendritic cells whose biology, clinical features, and treatment options are increasingly better understood.
    Recent findings: TCF4 is a master regulator that drives donwstream transcriptional programs in BPDCN. In turn, TCF4 activity is dependent on the bromodomain and extra-terminal domain (BET) protein BRD4 whose inhibition provides a promising therapeutic vulnerability. Notably, TCF4 expression is a highly sensitive marker for BPDCN and augments diagnostic specificity alongside CD4, CD56, CD123, and TCL1. The gene expression profile of BPDCN is characterized by aberrant NF-kappaB pathway activation, while its genomic landscape is dominated by structural chromosomal alterations involving ETV6, MYC, and NR3C1, as well as mutations in epigenetic regulators particularly TET2. Advances in elucidating the biological characteristics of BPDCN are resulting in a more refined diagnostic approach and are opening novel therapeutic avenues for patients with this disease.
    MeSH term(s) Dendritic Cells/pathology ; Hematologic Neoplasms/genetics ; Hematologic Neoplasms/pathology ; Humans
    Language English
    Publishing date 2018-10-22
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2229765-0
    ISSN 1558-822X ; 1558-8211
    ISSN (online) 1558-822X
    ISSN 1558-8211
    DOI 10.1007/s11899-018-0489-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma.

    Tashakori, Mehrnoosh / Khoury, Joseph D

    Blood

    2021  Volume 136, Issue 23, Page(s) 2720

    MeSH term(s) Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Autografts ; Female ; Humans ; Lenalidomide/administration & dosage ; Maintenance Chemotherapy ; Multiple Myeloma/metabolism ; Multiple Myeloma/pathology ; Multiple Myeloma/therapy ; Neoplasms, Second Primary/metabolism ; Neoplasms, Second Primary/pathology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Stem Cell Transplantation
    Chemical Substances Antibodies, Monoclonal, Humanized ; elotuzumab (1351PE5UGS) ; Lenalidomide (F0P408N6V4)
    Language English
    Publishing date 2021-02-09
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2020009141
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Myeloid diseases in the lung and pleura.

    Khoury, Joseph D / Chen, Weina

    Seminars in diagnostic pathology

    2020  Volume 37, Issue 6, Page(s) 296–302

    Abstract: Myeloid diseases detected as primary or secondary lesions in the lung and pleura are rare. Clinical presentations and radiographic results may vary significantly depending on the nature of the diseases. The most common diseases associated with lung and ... ...

    Abstract Myeloid diseases detected as primary or secondary lesions in the lung and pleura are rare. Clinical presentations and radiographic results may vary significantly depending on the nature of the diseases. The most common diseases associated with lung and pleura involvement are myeloid sarcoma/acute myeloid leukemia (AML) and extramedullary hematopoiesis (EMH). AML typically represents localized involvement by systemic acute leukemia, while EMH is frequently secondary to underlying benign hematolymphoid disorders or myeloproliferative neoplasms. This review provides an overview of the pathogenesis, clinical presentations, radiologic/imaging studies, pathologic and genetic findings, and treatment/outcomes associated with myeloid diseases in the lung and pleura.
    MeSH term(s) Diagnosis, Differential ; Genetic Predisposition to Disease ; Hematopoiesis, Extramedullary/genetics ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Lung/pathology ; Myeloproliferative Disorders/diagnosis ; Myeloproliferative Disorders/genetics ; Myeloproliferative Disorders/pathology ; Myeloproliferative Disorders/therapy ; Pathology, Molecular ; Pleura/pathology ; Sarcoma, Myeloid/diagnosis ; Sarcoma, Myeloid/genetics ; Sarcoma, Myeloid/pathology ; Sarcoma, Myeloid/therapy ; Thalassemia/diagnosis ; Thalassemia/genetics ; Thalassemia/pathology ; Thalassemia/therapy ; Treatment Outcome
    Language English
    Publishing date 2020-06-12
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 605834-6
    ISSN 1930-1111 ; 0740-2570
    ISSN (online) 1930-1111
    ISSN 0740-2570
    DOI 10.1053/j.semdp.2020.06.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: The evolving potential of companion diagnostics.

    Khoury, Joseph D

    Scandinavian journal of clinical and laboratory investigation. Supplementum

    2016  Volume 245, Page(s) S22–5

    Abstract: The scope of companion diagnostics in cancer has undergone significant shifts in the past few years, with increased development of targeted therapies and novel testing platforms. This has provided new opportunities to effect unprecedented paradigm shifts ...

    Abstract The scope of companion diagnostics in cancer has undergone significant shifts in the past few years, with increased development of targeted therapies and novel testing platforms. This has provided new opportunities to effect unprecedented paradigm shifts in the application of personalized medicine principles for patients with cancer. These shifts involve assay platforms, analytes, regulations, and therapeutic approaches. As opportunities involving each of these facets of companion diagnostics expand, close collaborations between key stakeholders should be enhanced to ensure optimal performance characteristics and patient outcomes.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Biological Assay/standards ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Clinical Trials as Topic ; DNA, Neoplasm/genetics ; DNA, Neoplasm/metabolism ; Humans ; Molecular Diagnostic Techniques/instrumentation ; Molecular Diagnostic Techniques/methods ; Molecular Targeted Therapy ; Neoplasms/diagnosis ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/pathology ; Precision Medicine/instrumentation ; Precision Medicine/methods ; RNA, Neoplasm/genetics ; RNA, Neoplasm/metabolism ; Research Design
    Chemical Substances Antineoplastic Agents ; Biomarkers, Tumor ; DNA, Neoplasm ; RNA, Neoplasm
    Language English
    Publishing date 2016
    Publishing country Norway
    Document type Journal Article
    ISSN 2166-1030
    ISSN (online) 2166-1030
    DOI 10.1080/00365513.2016.1206444
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top